ESC 2024 - Brendon Neuen, MBBS, PhD: Expanding Evidence of Combination Therapy with GLP-1 RAs and SGLT2 Inhibitors
Data from a systematic review and meta-analysis of placebo-controlled outcome trials of GLP-1 receptor agonists in type 2 diabetes is shedding further light on the effects of combination therapy with the class and SGLT2 inhibitors.
Leveraging data from around 17,000 patients, including more than 1700 using both GLP-1 receptor agonists and SGLT1 inhibitors, results of the study, which were presented at the European Society of Cardiology (ESC) Congress 2024, indicate both classes provide distinct cardiovascular and kidney benefits while also offering evidence of the consistency of GLP-1 receptor agonists’ benefit across different patient populations in type 2 diabetes.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
